SEC Form 4 · accession 0001104659-18-022155
Nabriva Therapeutics plc · NBRV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jennifer Schranz
Officer — Chief Medical Officer
Period of report
Mar 30, 2018
Accepted (ET)
Apr 3, 2018 · 4:08 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001641640
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1,F2 | — | Mar 30, 2018 | A | 150,000 | A | — | Mar 30, 2028 | Ordinary Shares | 150,000 | 150,000 | D |
Explanation of responses
- F1The exercise price is $5.03 per share.
- F2This option was granted on March 30, 2018. Vesting will begin on March 30, 2018 and end on March 31, 2022. Twenty-five percent (25%) of the option will vest on March 31, 2019, and the remaining seventy-five percent (75%) will vest on a monthly pro-rata basis over the remaining vesting period.